LongeVC

LongeVC is a venture capital firm investing in an ageless future. Through supporting exceptional early stage founders, our mission is to bring breakthrough biotech to market : the science that will change lives and transform our health.

LongeVC is a venture capital firm specializing in early-stage investments in biotechnology, with a strong focus on longevity and age-related innovations. The firm targets breakthrough startups in biotech, life sciences, and therapeutics that aim to extend human healthspan and address aging-related diseases. LongeVC invests primarily in Europe, the U.S., and Israel, typically providing between €0.5 million and €2.3 million per company. Its mission is to bring life-changing health technologies to market, supported by a deep scientific advisory board and rigorous scientific due diligence. The firm also offers strategic business development support to help founders scale globally impactful businesses[1][2].

Founded in 2020, LongeVC is led by partners including Ilya Suharenko, Garri Zmudze, and Sergey Jakimov. The firm has evolved to focus on three primary areas within longevity biotech: therapeutics, early-stage diagnostics, and longevity infrastructure. Its portfolio includes notable companies such as Insilico Medicine, an AI-driven drug discovery platform, and Rubedo Life Sciences, which targets the root causes of age-related diseases. LongeVC also supports diagnostics firms and software companies that streamline clinical trials, reflecting a broad approach to longevity innovation[1][2][4].

Core Differentiators

• Unique investment model: Focus on early-stage biotech startups specifically addressing longevity and age-related health challenges.
• Network strength: Supported by a robust scientific advisory board with expertise in gerontology, redox medicine, and biotech startup advising.
• Track record: Investments in high-profile companies like Insilico Medicine and Rubedo Life Sciences, which have raised significant funding rounds.
• Operating support: Provides strategic business development and scientific due diligence to ensure responsible, future-facing investments[1][2][3].

Role in the Broader Tech Landscape

LongeVC rides the growing trend of longevity biotech, driven by demographic shifts and increasing demand for healthy aging solutions. The timing is favorable due to advances in AI, diagnostics, and therapeutics that enable targeting fundamental aging processes. Market forces such as rising healthcare costs and aging populations create strong incentives for innovation in this space. By investing early in transformative technologies and supporting ecosystem-building organizations like Longevity.Technology, LongeVC influences the broader biotech and longevity ecosystem, helping to mainstream longevity science and accelerate clinical adoption[2][3].

Quick Take & Future Outlook

Looking ahead, LongeVC is poised to expand its portfolio and deepen its impact as longevity biotech gains momentum. Trends such as epigenetic reprogramming, senescent cell therapies, and AI-driven drug discovery will shape its investment focus. The firm’s commitment to rigorous scientific evaluation and ecosystem development suggests it will continue to play a pivotal role in advancing longevity innovations from early research to market. Its influence is likely to grow as public awareness and regulatory frameworks evolve, potentially making longevity a mainstream healthcare priority[2][3].